5 recruiting, 3 completed, 3 terminated, 1 active not recruiting. 15 Phase 1, 3 Phase 2.
Follow Urothelial Carcinoma Bladder: new trials by email Literature Review of Urothelial Carcinoma Bladder trials Research Report on Urothelial Carcinoma Bladder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial Calcium electroporation, Intratumoral calcium injection, Transurethral electroporation - Bladder Tumors, Bladder Tumor | Phase 1 | Recruiting | Juan Luis Vásquez | 20 | 2026-10-12 | 2026-10-27 |
| A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC UGN-501 - Bladder (Urothelial, Transitional Cell) Cancer, NMIBC | Phase 1 | Recruiting | UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. | 30 | 2026-09-28 | 2026-10-13 |
| A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 RNDO-564, Pembrolizumab - Non Small Cell Lung Cancer, Cervical Cancer | Phase 1 | Enrolling by invitation | Rondo Therapeutics | 149 | 2025-11-17 | 2026-06-11 |
| A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging) - Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC) | Phase 1 | Recruiting | Aktis Oncology, Inc. | 150 | 2025-08-22 | 2026-09-17 |
| A Tumor Immune Biomarker Guided Approach for Improving Response to BCG in Patients With High-risk NMIBC. Gemcitabine + BCG, BCG (TICE strain) - NMIBC, Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Queen's University | 31 | 2025-08-01 | 2025-07-17 |
| Intervention of Bladder Cancer by CAR-T 4SCAR-PSMA, 4SCAR-FRa - Bladder Cancer, Urothelial Carcinoma Bladder | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 20 | 2025-08-01 | 2026-10-30 |
| Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer Concurrent Immunotherapy and Radiation Therapy - Urothelial Carcinoma Bladder, Bladder Cancer | Phase 1 | Recruiting | Abramson Cancer Center at Penn Medicine | 10 | 2025-04-29 | 2026-05-14 |
| Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors BL-M17D1 - Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer | Phase 1 | Terminated | SystImmune Inc. | 3 | 2025-04-10 | 2026-09-22 |
| A Study of VET3-TGI in Patients With Solid Tumors VET3-TGI, Atezolizumab - Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer | Phase 1 | Recruiting | KaliVir Immunotherapeutics | 60 | 2024-09-16 | 2026-04-07 |
| Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant Degarelix, Gemcitabine/Cisplatin - Urothelial Carcinoma Bladder, Androgen Receptor Positive | Phase 1 | Terminated | Brown University | 2 | 2023-10-02 | 2026-04-02 |
| Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss Milademetan, Atezolizumab - Advanced Solid Tumor, CDKN2A | Phase 1 / Phase 2 | Withdrawn | Rain Oncology Inc | 2023-05-19 | 2023-10-19 | |
| A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer AU-011, AU-011 in Combination with Medical Laser Adminstration, AU-011 in Combination with Medical Laser Administration - Non-muscle-invasive Bladder Cancer, NMIBC | Phase 1 | Active not recruiting | Aura Biosciences | 55 | 2022-09-26 | 2026-08-06 |
| A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) UGN-301, UGN-201, Gemcitabine - Non-muscle Invasive Bladder Cancer, NMIBC | Phase 1 | Completed | UroGen Pharma Ltd. | 51 | 2022-06-01 | 2026-01-14 |
| A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma IK-175, IK-175 and nivolumab - Urothelial Carcinoma, Urothelial Carcinoma Bladder | Phase 1 | Completed | Ikena Oncology | 78 | 2019-12-18 | 2024-03-15 |
| Phase Ib of L-NMMA and Pembrolizumab L-NMMA, Pembrolizumab - Non-Small Cell Lung Cancer, Malignant Melanoma | Phase 1 | Completed | The Methodist Hospital Research Institute | 12 | 2018-08-27 | 2026-04-09 |
Urinary Bladder Neoplasms (8) · Carcinoma, Non-Small-Cell Lung (5) · Neoplasms (4) · Non-Muscle Invasive Bladder Neoplasms (4) · Melanoma (3) · Squamous Cell Carcinoma of Head and Neck (3) · Stomach Neoplasms (3) · Carcinoma, Renal Cell (2) · Carcinoma, Transitional Cell (2) · Mesothelioma (2) · Triple Negative Breast Neoplasms (2) · Uterine Cervical Neoplasms (2) · Adenocarcinoma (1) · Breast Neoplasms (1) · Carcinoma, Squamous Cell (1)
Neoplasms by Site (15) · Female Urogenital Diseases (13) · Female Urogenital Diseases and Pregnancy Complications (13) · Urogenital Diseases (13) · Urogenital Neoplasms (13) · Male Urogenital Diseases (12) · Urologic Diseases (12) · Urologic Neoplasms (12) · Neoplasms (11) · Carcinoma (10) · Neoplasms by Histologic Type (10) · Neoplasms, Glandular and Epithelial (10) · Urinary Bladder Diseases (9) · Skin Diseases (6) · Skin and Connective Tissue Diseases (6)
Gemcitabine (3) · atezolizumab (2) · pembrolizumab (2) · BCG Vaccine (1) · Cisplatin (1) · Imiquimod (1) · Nivolumab (1) · Radiotherapy (1) · Therapeutics (1) · X-Rays (1) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (1) · milademetan (1) · omega-N-Methylarginine (1)
Abramson Cancer Center at Penn Medicine (1) · Aktis Oncology, Inc. (1) · Aura Biosciences (1) · Brown University (1) · Ikena Oncology (1) · Juan Luis Vásquez (1) · KaliVir Immunotherapeutics (1) · Queen's University (1) · Rain Oncology Inc (1) · Rondo Therapeutics (1) · Shenzhen Geno-Immune Medical Institute (1) · SystImmune Inc. (1) · The Methodist Hospital Research Institute (1) · UroGen Pharma Ltd. (1) · UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. (1)
United States (11) · Australia (1) · Canada (1) · China (1) · Denmark (1) · Italy (1) · Spain (1)
Sebastian Mirkin, MD (2) · John Christodouleas, MD (1) · Jun Zhang, M.D. (1) · Karim Malek, MD (1) · Lung-Ji Chang, PhD (1) · Sarah Tannenbaum, MD, MSc (1) · Sheldon L Holder, MD, PhD (1) · Thomas Manley, MD (1)